Condition: Vitamin K-Dependent Coagulation Defect · Significant Bleeding Risk · Sponsor: Octapharma
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
This description comes directly from the study's public registry record.
Patrick Murphy · 8663371868 · p.murphy@crmg-usa.com
Always discuss trial participation with your own doctor first.
| Octapharma Research Site | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06429787